( bi- ormultivalent binding formats suc...)Pieris Progresses Development of its Proprietary Biotherapeutics,Platform: Successful Demonstration of Dual Targeting With,Duocalin(R) Technology,Health

bi- or multivalent binding formats such as Duocalins(R) have significant potential in targeting cell surface molecules in disease, mediating agonistic effects on signal transduction pathways or inducing enhanced internalization effects via binding and clustering of cell surface receptors.

The data will be presented for the first time on June 25th 2007 at IBC's second annual "Beyond Antibodies" Conference in Coronado, CA, USA.

Notes to Editors

About Pieris AG

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins, a novel class of targeted protein therapeutics, for the diagnosis and treatment of life-threatening human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of its Anticalin candidates.

About the Anticalin(R) technology

Anticalins are derived from the lipocalin scaffold, originally developed by Prof. Dr. Arne Skerra, a leading expert in the field and Head of the Department of Biological Chemistry at the Technical University of Munich, Germany. As engineered human proteins, Anticalins have prescribed binding properties with fundamental similarities to fully human antibodies e.g. picomolar potency and expected low immunogenicity. Anticalins have several additional advantages over conventional antibodies due to their small size (20 kDa), robust tertiary structure and straight composition that confer high solubility, predictable stability and bacterial manufacturability. Fast pharmaco-kinetics and favorable tissue penetration of Anticalins can be balanced through adjustable modulation of serum half-life.

Pieris and its collaborators are not only able to develop superior biotherapeutics, but they also have the ability to overcome the encumbering patent landscape as currently present for the development of conventional antibodies.

About
'"/>

Page: 1 2 3
Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific Anticalin in Preclinical Studies
3. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
4. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
5. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
6. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
7. CuraGen Presents Update on Clinical Development Program for Belinostat
8. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
9. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
10. ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting
11. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer